This phase II randomized trial studies the side effects and how well metformin hydrochloride works in reducing obesity-associated breast cancer risk. Metformin hydrochloride may help prevent, stop, or delay breast cancer from forming by reducing some of the risk factors associated with breast cancer such as breast density, certain proteins and hormones, certain metabolites produced by the body, body weight, and waist and hip sizes.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02028221.
PRIMARY OBJECTIVE:
I. To determine the effect of metformin (metformin hydrochloride) intervention on breast density assessed by magnetic resonance imaging (MRI)-acquired fat-to-water ratio (FWR-MRI).
SECONDARY OBJECTIVES:
I. To determine the effect of metformin intervention on metabolic disturbances and body weight/composition.
II. To explore the application of metabolomics as a systems biology approach to assess the chemopreventive mechanisms of metformin.
EXPLORATORY OBJECTIVE:
I. To determine the effect of metformin intervention on tissue architecture as well as cellular and molecular targets in breast tissue collected in a subgroup of participants.
OUTLINE: Participants are randomized to 1 of 2 treatment arms.
ARM I: Participants receive metformin hydrochloride orally (PO) once daily (QD) for 4 weeks. Participants then receive metformin hydrochloride PO QD or twice daily (BID). Treatment continues for 12 months in the absence of disease progression or unacceptable toxicity.
ARM II: Participants receive placebo PO QD for 4 weeks. Participants then receive placebo PO QD or BID. Treatment continues for 12 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up for 2 weeks.
Lead OrganizationBanner University Medical Center - Tucson
Principal InvestigatorHsiao-Hui (Sherry) Chow